Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1002/phar.2403 http://scihub22266oqcxt.onion/10.1002/phar.2403 32281114!7262085!32281114     free     free     free Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=32281114&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Pharmacotherapy 2020 ; 40 (6): 592-598 Nephropedia Template TP {{tp|p=32281114|t=2020. Delayed Initiation of Remdesivir in a COVID-19-Positive Patient |pdf=|usr=}}{{32281114}} gab.com Text Delayed Initiation of Remdesivir in a COVID-19-Positive Patient JO: Pharmacotherapy http://www.kidney.de/pget.php?&tw=1&pmid=32281114 #FOAvip We present a case of late initiation of remdesivir antiviral therapy in the successful treatment of a patient with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in a mixed medical intensive care unit of a community teaching hospital. A previously healthy 40-year-old man was admitted to the hospital 3 days after the onset of coronavirus disease 2019 (COVID-19) symptoms including dry cough, fever, and shortness of breath progressing to intubation and increased mechanical ventilator support. A request for compassionate use remdesivir was submitted on the same hospital day as the positive COVID-19 polymerase chain reaction result. Supportive measures, in addition to a 5-day course of hydroxychloroquine, were maintained until remdesivir could be supplied on day 9 of hospitalization, 13 days after symptom onset. Sixty hours after initiating remdesivir, the patient was successfully extubated and able to transition to room air within 24 hours of extubation. Late initiation of remdesivir may be effective in treating SARS-CoV-2, unlike antivirals utilized for different disease states, such as oseltamivir, that are most effective when started as soon as possible following symptom onset. Urgent action is needed by regulatory agencies to work with drug manufacturers to expedite the study and approval of investigational agents targeting SARS-CoV-2 as well as to meet manufacturing demands. Twit Text FOAVip Delayed Initiation of Remdesivir in a COVID-19-Positive Patient ????Pharmacotherapy http://www.kidney.de/pget.php?&tw=1&pmid=32281114 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32281114 #FOAvip English Wikipedia <ref>{{Cite pmid|32281114}}</ref> Delayed Initiation of Remdesivir in a COVID-19-Positive Patient #MMPMID32281114 Hillaker E; Belfer JJ; Bondici A; Murad H; Dumkow LE Pharmacotherapy 2020[Jun]; 40 (6): 592-598 PMID32281114show ga We present a case of late initiation of remdesivir antiviral therapy in the successful treatment of a patient with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in a mixed medical intensive care unit of a community teaching hospital. A previously healthy 40-year-old man was admitted to the hospital 3 days after the onset of coronavirus disease 2019 (COVID-19) symptoms including dry cough, fever, and shortness of breath progressing to intubation and increased mechanical ventilator support. A request for compassionate use remdesivir was submitted on the same hospital day as the positive COVID-19 polymerase chain reaction result. Supportive measures, in addition to a 5-day course of hydroxychloroquine, were maintained until remdesivir could be supplied on day 9 of hospitalization, 13 days after symptom onset. Sixty hours after initiating remdesivir, the patient was successfully extubated and able to transition to room air within 24 hours of extubation. Late initiation of remdesivir may be effective in treating SARS-CoV-2, unlike antivirals utilized for different disease states, such as oseltamivir, that are most effective when started as soon as possible following symptom onset. Urgent action is needed by regulatory agencies to work with drug manufacturers to expedite the study and approval of investigational agents targeting SARS-CoV-2 as well as to meet manufacturing demands. |Adenosine Monophosphate/administration & dosage/*analogs & derivatives/therapeutic use[MESH] |Adult[MESH] |Alanine/administration & dosage/*analogs & derivatives/therapeutic use[MESH] |Antimalarials/therapeutic use[MESH] |Antiviral Agents/administration & dosage/*therapeutic use[MESH] |Betacoronavirus[MESH] |COVID-19[MESH] |Coronavirus Infections/*drug therapy[MESH] |Humans[MESH] |Hydroxychloroquine/therapeutic use[MESH] |Male[MESH] |Pandemics[MESH] |Pneumonia, Viral/*drug therapy[MESH] |SARS-CoV-2[MESH] |Time Factors[MESH]Delayed Initiation of Remdesivir in a COVID-19-Positive Patient (epmc).pdf DeepDyve Pubget Overpricing